Abstract
© 2020 The Author(s)
PDF Article© 2020 The Author(s)
PDF Article
S. Schäfermann, E. Wemakor, C. Hauk, L. Heide. “Quality of Medicines in Southern Togo: Investigation of Antibiotics and of Medicines for Non-Communicable Diseases from Pharmacies and Informal Vendors”. PLoS One. 2018, 13(11): E0207911.
N. Tshilombo, P. Hamuli, J. Mbinze, V. Habyalimana, et al. “Investigation of the Quality of Antibiotics-Based Amoxicillin for Monitoring of Some Different Medicine Markets of Democratic Republic of Congo”. Am. J. Anal. Chem. 2018, 9(8): 366–385.
F. Khuluza, S. Kigera, L. Heide. “Low Prevalence of Substandard and Falsified Antimalarial and Antibiotic Medicines in Public and Faith-Based Health Facilities of Southern Malawi”. Am. J. Trop. Med. Hyg. 2017, 96(5): 1124–1135.
H. Yang, B. Hu, X. Pan, S. Yan, et al. “Deep Belief Network-Based Drug Identification Using Near Infrared Spectroscopy”. J. Innov. Opt. Heal. Sci. 2017, 10(2): 1630011.
I. Fadeyi, M. Lalani, N. Mailk, A. Van Wyk, H. Kaur. “Quality of the Antibiotics—Amoxicillin and Co-Trimoxazole from Ghana, Nigeria, and the United Kingdom”. Am. Soc. Trop. Med. Hyg. 2015, 92(6): 87–94.
S. Bekoe, S. Bak, E. Björklund, K. Krogh, et al. “Determination of Thirteen Antibiotics in Drug Products: A New LC-MS/MS Tool for Screening Drug Product Quality”. Anal. Methods. 2014, 6(15): 5847–5855.
A. Pomerantsev, O. Rodionova. “Concept and Role of Extreme Objects in PCA/SIMCA”. J Chemom. 2014, 28(5): 429–438.
S. Kovacs, S. Hawes, S. Maley, E. Mosites, et al. “Technologies for Detecting Falsified and Substandard Drugs in Low and Middle-Income Countries”. PLoS One. 2014, 9(3): E90601.
O. Rodionova, K. Balyklova, A. Titova, A. Pomerantsev. “Quantitative Risk Assessment in Classification of Drugs with Identical API Content”. J. Pharm. Biomed. Anal. 2014, 98: 186–192.
A. Weaver, H. Reiser, T. Barstis, M. Benvenuti, et al. “Paper Analytical Devices for Fast Field Screening of Beta Lactam Antibiotics and Antituberculosis Pharmaceuticals”. Anal. Chem. 2013, 85(13): 6453–6460.
J. Mbinze, P. Lebrun, B. Debrus, A. Dispas, et al. “Application of an Innovative Design Space Optimization Strategy to the Development of Liquid Chromatographic Methods to Combat Potentially Counterfeit Nonsteroidal Anti-Inflammatory Drugs”. J. Chromatogr. A. 2012, 1263: 113–124.
A. Delepierre, A. Gayot, A. Carpentier. “Update On Counterfeit Antibiotics Worldwide; Public Health Risks”. Med. Maladies Infect. 2012, 42(6): 247–255.
S. Assi, R. Watt, A. Moffat. “Identification of Counterfeit Medicines from the Internet and the World Market Using Near-Infrared Spectroscopy”. Anal. Methods. 2011, 3(10): 2231–2236.
A. Moffat, S. Assi, R. Watt. “Identifying Counterfeit Medicines Using Near Infrared Spectroscopy”. J. Near Infrared Spectrosc. 2010, 18(1): 1–5.
B. Singh, D. Parwate, S. Shukla. “Rapid Color Test Identification System for Screening of Counterfeit Fluoroquinolone”. J. Chem. 2009, 6(2): 377–384.
S. Assi, R. Watt, A. Moffat. “Assay of Ciprofloxacin in Intact and Powdered Tablets by Near-Infrared Spectroscopy”. J. Pharm. Pharmacol. 2008, 60(S1): A7–A10.
T. Sakamoto, Y. Fujimaki, Y. Hiyama. “NIR Spectroscopic Investigation of Two Fluoroquinolones, Levofloxacin and Ofloxacin, and Their Tablets for Qualitative Identification of Commercial Products on the Market”. Die Pharmazie. 2008, 63(9): 628–632.
A. Solangi, S. Memon, M. Khuhawar, M. Bhanger. “Quantitative Analysis of Eight Cephalosporin Antibiotics in Pharmaceutical Products and Urine by Capillary Zone Electrophoresis”. Acta Chromatogr. 2007, 19: 81–96.
T. Kelesidis, L. Kelesidis, P. Rafailidis, M. Falagas. “Counterfeit or Substandard Antimicrobial Drugs: A Review of the Scientific Evidence”. J. Antimicrob. Chemother. 2007, 60: 214–236.
R. Brereton. “Consequences of Sample Size, Variable Selection, and Model Validation and Optimization, for Predicting Classification Ability from Analytical Data”. TrAC, Trends Anal. Chem. 2006, 25(11): 1103–1111.
O. Rodionova, L. Houmøller, A. Pomerantsev, P. Geladi, et al. “NIR Spectrometry for Counterfeit Drug Detection: A Feasibility Study”. Anal. Chim. Acta. 2005, 549(1–2): 151–158.
H. Frankish. “WHO Steps Up Campaign on Counterfeit Drugs”. Lancet. 2003, 362(9397): 1730.
A. Po. “Too Much, Too Little, or None at All: Dealing with Substandard and Fake Drugs”. Lancet. 2001, 357(9272): 1904.
M. Issack. Substandard Drugs”. Lancet. 2001, 358(9291): 1463.
J. Videau. “Generic Drugs: the Hidden Issues of Quality and Cost”. WHO Drug Information. 2000, 14(2): 77–81.
L. Basco, P. Ringwald, A. Manéné, J. Chandenier. “False Chloroquine Resistance in Africa”. Lancet. 1997, 350(9072): 224.
O. Shakoor, R. Taylor, R. Behrens. “Assessment of the Incidence of Substandard Drugs in Developing Countries”. Trop. Med. Int. Health. 1997, 2(9): 839–845.
D. Menkes. Hazardous Drugs in Developing Countries: The Market May Be Healthier than the People.” Br. Med. J. 1997, 315(7122): 1557–1558.
S. Assi, R. Watt, A. Moffat. “Identification of Counterfeit Medicines from the Internet and the World Market Using Near-Infrared Spectroscopy”. Anal. Methods. 2011, 3(10): 2231–2236.
A. Moffat, S. Assi, R. Watt. “Identifying Counterfeit Medicines Using Near Infrared Spectroscopy”. J. Near Infrared Spectrosc. 2010, 18(1): 1–5.
S. Assi, R. Watt, A. Moffat. “Assay of Ciprofloxacin in Intact and Powdered Tablets by Near-Infrared Spectroscopy”. J. Pharm. Pharmacol. 2008, 60(S1): A7–A10.
S. Bekoe, S. Bak, E. Björklund, K. Krogh, et al. “Determination of Thirteen Antibiotics in Drug Products: A New LC-MS/MS Tool for Screening Drug Product Quality”. Anal. Methods. 2014, 6(15): 5847–5855.
O. Rodionova, K. Balyklova, A. Titova, A. Pomerantsev. “Quantitative Risk Assessment in Classification of Drugs with Identical API Content”. J. Pharm. Biomed. Anal. 2014, 98: 186–192.
A. Weaver, H. Reiser, T. Barstis, M. Benvenuti, et al. “Paper Analytical Devices for Fast Field Screening of Beta Lactam Antibiotics and Antituberculosis Pharmaceuticals”. Anal. Chem. 2013, 85(13): 6453–6460.
L. Basco, P. Ringwald, A. Manéné, J. Chandenier. “False Chloroquine Resistance in Africa”. Lancet. 1997, 350(9072): 224.
O. Shakoor, R. Taylor, R. Behrens. “Assessment of the Incidence of Substandard Drugs in Developing Countries”. Trop. Med. Int. Health. 1997, 2(9): 839–845.
S. Bekoe, S. Bak, E. Björklund, K. Krogh, et al. “Determination of Thirteen Antibiotics in Drug Products: A New LC-MS/MS Tool for Screening Drug Product Quality”. Anal. Methods. 2014, 6(15): 5847–5855.
A. Weaver, H. Reiser, T. Barstis, M. Benvenuti, et al. “Paper Analytical Devices for Fast Field Screening of Beta Lactam Antibiotics and Antituberculosis Pharmaceuticals”. Anal. Chem. 2013, 85(13): 6453–6460.
A. Solangi, S. Memon, M. Khuhawar, M. Bhanger. “Quantitative Analysis of Eight Cephalosporin Antibiotics in Pharmaceutical Products and Urine by Capillary Zone Electrophoresis”. Acta Chromatogr. 2007, 19: 81–96.
S. Bekoe, S. Bak, E. Björklund, K. Krogh, et al. “Determination of Thirteen Antibiotics in Drug Products: A New LC-MS/MS Tool for Screening Drug Product Quality”. Anal. Methods. 2014, 6(15): 5847–5855.
R. Brereton. “Consequences of Sample Size, Variable Selection, and Model Validation and Optimization, for Predicting Classification Ability from Analytical Data”. TrAC, Trends Anal. Chem. 2006, 25(11): 1103–1111.
A. Delepierre, A. Gayot, A. Carpentier. “Update On Counterfeit Antibiotics Worldwide; Public Health Risks”. Med. Maladies Infect. 2012, 42(6): 247–255.
L. Basco, P. Ringwald, A. Manéné, J. Chandenier. “False Chloroquine Resistance in Africa”. Lancet. 1997, 350(9072): 224.
J. Mbinze, P. Lebrun, B. Debrus, A. Dispas, et al. “Application of an Innovative Design Space Optimization Strategy to the Development of Liquid Chromatographic Methods to Combat Potentially Counterfeit Nonsteroidal Anti-Inflammatory Drugs”. J. Chromatogr. A. 2012, 1263: 113–124.
A. Delepierre, A. Gayot, A. Carpentier. “Update On Counterfeit Antibiotics Worldwide; Public Health Risks”. Med. Maladies Infect. 2012, 42(6): 247–255.
J. Mbinze, P. Lebrun, B. Debrus, A. Dispas, et al. “Application of an Innovative Design Space Optimization Strategy to the Development of Liquid Chromatographic Methods to Combat Potentially Counterfeit Nonsteroidal Anti-Inflammatory Drugs”. J. Chromatogr. A. 2012, 1263: 113–124.
I. Fadeyi, M. Lalani, N. Mailk, A. Van Wyk, H. Kaur. “Quality of the Antibiotics—Amoxicillin and Co-Trimoxazole from Ghana, Nigeria, and the United Kingdom”. Am. Soc. Trop. Med. Hyg. 2015, 92(6): 87–94.
T. Kelesidis, L. Kelesidis, P. Rafailidis, M. Falagas. “Counterfeit or Substandard Antimicrobial Drugs: A Review of the Scientific Evidence”. J. Antimicrob. Chemother. 2007, 60: 214–236.
K. Varmuza, P. Filzmoser. Introduction to Multivariate Statistical Analysis in Chemometrics., Boca Raton, FL: CRC Press, 2016.
H. Frankish. “WHO Steps Up Campaign on Counterfeit Drugs”. Lancet. 2003, 362(9397): 1730.
T. Sakamoto, Y. Fujimaki, Y. Hiyama. “NIR Spectroscopic Investigation of Two Fluoroquinolones, Levofloxacin and Ofloxacin, and Their Tablets for Qualitative Identification of Commercial Products on the Market”. Die Pharmazie. 2008, 63(9): 628–632.
A. Delepierre, A. Gayot, A. Carpentier. “Update On Counterfeit Antibiotics Worldwide; Public Health Risks”. Med. Maladies Infect. 2012, 42(6): 247–255.
O. Rodionova, L. Houmøller, A. Pomerantsev, P. Geladi, et al. “NIR Spectrometry for Counterfeit Drug Detection: A Feasibility Study”. Anal. Chim. Acta. 2005, 549(1–2): 151–158.
N. Tshilombo, P. Hamuli, J. Mbinze, V. Habyalimana, et al. “Investigation of the Quality of Antibiotics-Based Amoxicillin for Monitoring of Some Different Medicine Markets of Democratic Republic of Congo”. Am. J. Anal. Chem. 2018, 9(8): 366–385.
N. Tshilombo, P. Hamuli, J. Mbinze, V. Habyalimana, et al. “Investigation of the Quality of Antibiotics-Based Amoxicillin for Monitoring of Some Different Medicine Markets of Democratic Republic of Congo”. Am. J. Anal. Chem. 2018, 9(8): 366–385.
S. Schäfermann, E. Wemakor, C. Hauk, L. Heide. “Quality of Medicines in Southern Togo: Investigation of Antibiotics and of Medicines for Non-Communicable Diseases from Pharmacies and Informal Vendors”. PLoS One. 2018, 13(11): E0207911.
S. Kovacs, S. Hawes, S. Maley, E. Mosites, et al. “Technologies for Detecting Falsified and Substandard Drugs in Low and Middle-Income Countries”. PLoS One. 2014, 9(3): E90601.
S. Schäfermann, E. Wemakor, C. Hauk, L. Heide. “Quality of Medicines in Southern Togo: Investigation of Antibiotics and of Medicines for Non-Communicable Diseases from Pharmacies and Informal Vendors”. PLoS One. 2018, 13(11): E0207911.
F. Khuluza, S. Kigera, L. Heide. “Low Prevalence of Substandard and Falsified Antimalarial and Antibiotic Medicines in Public and Faith-Based Health Facilities of Southern Malawi”. Am. J. Trop. Med. Hyg. 2017, 96(5): 1124–1135.
T. Sakamoto, Y. Fujimaki, Y. Hiyama. “NIR Spectroscopic Investigation of Two Fluoroquinolones, Levofloxacin and Ofloxacin, and Their Tablets for Qualitative Identification of Commercial Products on the Market”. Die Pharmazie. 2008, 63(9): 628–632.
O. Rodionova, L. Houmøller, A. Pomerantsev, P. Geladi, et al. “NIR Spectrometry for Counterfeit Drug Detection: A Feasibility Study”. Anal. Chim. Acta. 2005, 549(1–2): 151–158.
H. Yang, B. Hu, X. Pan, S. Yan, et al. “Deep Belief Network-Based Drug Identification Using Near Infrared Spectroscopy”. J. Innov. Opt. Heal. Sci. 2017, 10(2): 1630011.
M. Issack. Substandard Drugs”. Lancet. 2001, 358(9291): 1463.
I. Fadeyi, M. Lalani, N. Mailk, A. Van Wyk, H. Kaur. “Quality of the Antibiotics—Amoxicillin and Co-Trimoxazole from Ghana, Nigeria, and the United Kingdom”. Am. Soc. Trop. Med. Hyg. 2015, 92(6): 87–94.
T. Kelesidis, L. Kelesidis, P. Rafailidis, M. Falagas. “Counterfeit or Substandard Antimicrobial Drugs: A Review of the Scientific Evidence”. J. Antimicrob. Chemother. 2007, 60: 214–236.
T. Kelesidis, L. Kelesidis, P. Rafailidis, M. Falagas. “Counterfeit or Substandard Antimicrobial Drugs: A Review of the Scientific Evidence”. J. Antimicrob. Chemother. 2007, 60: 214–236.
A. Solangi, S. Memon, M. Khuhawar, M. Bhanger. “Quantitative Analysis of Eight Cephalosporin Antibiotics in Pharmaceutical Products and Urine by Capillary Zone Electrophoresis”. Acta Chromatogr. 2007, 19: 81–96.
F. Khuluza, S. Kigera, L. Heide. “Low Prevalence of Substandard and Falsified Antimalarial and Antibiotic Medicines in Public and Faith-Based Health Facilities of Southern Malawi”. Am. J. Trop. Med. Hyg. 2017, 96(5): 1124–1135.
F. Khuluza, S. Kigera, L. Heide. “Low Prevalence of Substandard and Falsified Antimalarial and Antibiotic Medicines in Public and Faith-Based Health Facilities of Southern Malawi”. Am. J. Trop. Med. Hyg. 2017, 96(5): 1124–1135.
S. Kovacs, S. Hawes, S. Maley, E. Mosites, et al. “Technologies for Detecting Falsified and Substandard Drugs in Low and Middle-Income Countries”. PLoS One. 2014, 9(3): E90601.
S. Bekoe, S. Bak, E. Björklund, K. Krogh, et al. “Determination of Thirteen Antibiotics in Drug Products: A New LC-MS/MS Tool for Screening Drug Product Quality”. Anal. Methods. 2014, 6(15): 5847–5855.
I. Fadeyi, M. Lalani, N. Mailk, A. Van Wyk, H. Kaur. “Quality of the Antibiotics—Amoxicillin and Co-Trimoxazole from Ghana, Nigeria, and the United Kingdom”. Am. Soc. Trop. Med. Hyg. 2015, 92(6): 87–94.
J. Mbinze, P. Lebrun, B. Debrus, A. Dispas, et al. “Application of an Innovative Design Space Optimization Strategy to the Development of Liquid Chromatographic Methods to Combat Potentially Counterfeit Nonsteroidal Anti-Inflammatory Drugs”. J. Chromatogr. A. 2012, 1263: 113–124.
I. Fadeyi, M. Lalani, N. Mailk, A. Van Wyk, H. Kaur. “Quality of the Antibiotics—Amoxicillin and Co-Trimoxazole from Ghana, Nigeria, and the United Kingdom”. Am. Soc. Trop. Med. Hyg. 2015, 92(6): 87–94.
S. Kovacs, S. Hawes, S. Maley, E. Mosites, et al. “Technologies for Detecting Falsified and Substandard Drugs in Low and Middle-Income Countries”. PLoS One. 2014, 9(3): E90601.
L. Basco, P. Ringwald, A. Manéné, J. Chandenier. “False Chloroquine Resistance in Africa”. Lancet. 1997, 350(9072): 224.
N. Tshilombo, P. Hamuli, J. Mbinze, V. Habyalimana, et al. “Investigation of the Quality of Antibiotics-Based Amoxicillin for Monitoring of Some Different Medicine Markets of Democratic Republic of Congo”. Am. J. Anal. Chem. 2018, 9(8): 366–385.
J. Mbinze, P. Lebrun, B. Debrus, A. Dispas, et al. “Application of an Innovative Design Space Optimization Strategy to the Development of Liquid Chromatographic Methods to Combat Potentially Counterfeit Nonsteroidal Anti-Inflammatory Drugs”. J. Chromatogr. A. 2012, 1263: 113–124.
A. Solangi, S. Memon, M. Khuhawar, M. Bhanger. “Quantitative Analysis of Eight Cephalosporin Antibiotics in Pharmaceutical Products and Urine by Capillary Zone Electrophoresis”. Acta Chromatogr. 2007, 19: 81–96.
D. Menkes. Hazardous Drugs in Developing Countries: The Market May Be Healthier than the People.” Br. Med. J. 1997, 315(7122): 1557–1558.
S. Assi, R. Watt, A. Moffat. “Identification of Counterfeit Medicines from the Internet and the World Market Using Near-Infrared Spectroscopy”. Anal. Methods. 2011, 3(10): 2231–2236.
A. Moffat, S. Assi, R. Watt. “Identifying Counterfeit Medicines Using Near Infrared Spectroscopy”. J. Near Infrared Spectrosc. 2010, 18(1): 1–5.
S. Assi, R. Watt, A. Moffat. “Assay of Ciprofloxacin in Intact and Powdered Tablets by Near-Infrared Spectroscopy”. J. Pharm. Pharmacol. 2008, 60(S1): A7–A10.
S. Kovacs, S. Hawes, S. Maley, E. Mosites, et al. “Technologies for Detecting Falsified and Substandard Drugs in Low and Middle-Income Countries”. PLoS One. 2014, 9(3): E90601.
H. Yang, B. Hu, X. Pan, S. Yan, et al. “Deep Belief Network-Based Drug Identification Using Near Infrared Spectroscopy”. J. Innov. Opt. Heal. Sci. 2017, 10(2): 1630011.
B. Singh, D. Parwate, S. Shukla. “Rapid Color Test Identification System for Screening of Counterfeit Fluoroquinolone”. J. Chem. 2009, 6(2): 377–384.
A. Po. “Too Much, Too Little, or None at All: Dealing with Substandard and Fake Drugs”. Lancet. 2001, 357(9272): 1904.
A. Pomerantsev, O. Rodionova. “Concept and Role of Extreme Objects in PCA/SIMCA”. J Chemom. 2014, 28(5): 429–438.
O. Rodionova, K. Balyklova, A. Titova, A. Pomerantsev. “Quantitative Risk Assessment in Classification of Drugs with Identical API Content”. J. Pharm. Biomed. Anal. 2014, 98: 186–192.
O. Rodionova, L. Houmøller, A. Pomerantsev, P. Geladi, et al. “NIR Spectrometry for Counterfeit Drug Detection: A Feasibility Study”. Anal. Chim. Acta. 2005, 549(1–2): 151–158.
T. Kelesidis, L. Kelesidis, P. Rafailidis, M. Falagas. “Counterfeit or Substandard Antimicrobial Drugs: A Review of the Scientific Evidence”. J. Antimicrob. Chemother. 2007, 60: 214–236.
A. Weaver, H. Reiser, T. Barstis, M. Benvenuti, et al. “Paper Analytical Devices for Fast Field Screening of Beta Lactam Antibiotics and Antituberculosis Pharmaceuticals”. Anal. Chem. 2013, 85(13): 6453–6460.
L. Basco, P. Ringwald, A. Manéné, J. Chandenier. “False Chloroquine Resistance in Africa”. Lancet. 1997, 350(9072): 224.
A. Pomerantsev, O. Rodionova. “Concept and Role of Extreme Objects in PCA/SIMCA”. J Chemom. 2014, 28(5): 429–438.
O. Rodionova, K. Balyklova, A. Titova, A. Pomerantsev. “Quantitative Risk Assessment in Classification of Drugs with Identical API Content”. J. Pharm. Biomed. Anal. 2014, 98: 186–192.
O. Rodionova, L. Houmøller, A. Pomerantsev, P. Geladi, et al. “NIR Spectrometry for Counterfeit Drug Detection: A Feasibility Study”. Anal. Chim. Acta. 2005, 549(1–2): 151–158.
T. Sakamoto, Y. Fujimaki, Y. Hiyama. “NIR Spectroscopic Investigation of Two Fluoroquinolones, Levofloxacin and Ofloxacin, and Their Tablets for Qualitative Identification of Commercial Products on the Market”. Die Pharmazie. 2008, 63(9): 628–632.
S. Schäfermann, E. Wemakor, C. Hauk, L. Heide. “Quality of Medicines in Southern Togo: Investigation of Antibiotics and of Medicines for Non-Communicable Diseases from Pharmacies and Informal Vendors”. PLoS One. 2018, 13(11): E0207911.
O. Shakoor, R. Taylor, R. Behrens. “Assessment of the Incidence of Substandard Drugs in Developing Countries”. Trop. Med. Int. Health. 1997, 2(9): 839–845.
B. Singh, D. Parwate, S. Shukla. “Rapid Color Test Identification System for Screening of Counterfeit Fluoroquinolone”. J. Chem. 2009, 6(2): 377–384.
B. Singh, D. Parwate, S. Shukla. “Rapid Color Test Identification System for Screening of Counterfeit Fluoroquinolone”. J. Chem. 2009, 6(2): 377–384.
A. Solangi, S. Memon, M. Khuhawar, M. Bhanger. “Quantitative Analysis of Eight Cephalosporin Antibiotics in Pharmaceutical Products and Urine by Capillary Zone Electrophoresis”. Acta Chromatogr. 2007, 19: 81–96.
O. Shakoor, R. Taylor, R. Behrens. “Assessment of the Incidence of Substandard Drugs in Developing Countries”. Trop. Med. Int. Health. 1997, 2(9): 839–845.
O. Rodionova, K. Balyklova, A. Titova, A. Pomerantsev. “Quantitative Risk Assessment in Classification of Drugs with Identical API Content”. J. Pharm. Biomed. Anal. 2014, 98: 186–192.
N. Tshilombo, P. Hamuli, J. Mbinze, V. Habyalimana, et al. “Investigation of the Quality of Antibiotics-Based Amoxicillin for Monitoring of Some Different Medicine Markets of Democratic Republic of Congo”. Am. J. Anal. Chem. 2018, 9(8): 366–385.
I. Fadeyi, M. Lalani, N. Mailk, A. Van Wyk, H. Kaur. “Quality of the Antibiotics—Amoxicillin and Co-Trimoxazole from Ghana, Nigeria, and the United Kingdom”. Am. Soc. Trop. Med. Hyg. 2015, 92(6): 87–94.
K. Varmuza, P. Filzmoser. Introduction to Multivariate Statistical Analysis in Chemometrics., Boca Raton, FL: CRC Press, 2016.
J. Videau. “Generic Drugs: the Hidden Issues of Quality and Cost”. WHO Drug Information. 2000, 14(2): 77–81.
S. Assi, R. Watt, A. Moffat. “Identification of Counterfeit Medicines from the Internet and the World Market Using Near-Infrared Spectroscopy”. Anal. Methods. 2011, 3(10): 2231–2236.
A. Moffat, S. Assi, R. Watt. “Identifying Counterfeit Medicines Using Near Infrared Spectroscopy”. J. Near Infrared Spectrosc. 2010, 18(1): 1–5.
S. Assi, R. Watt, A. Moffat. “Assay of Ciprofloxacin in Intact and Powdered Tablets by Near-Infrared Spectroscopy”. J. Pharm. Pharmacol. 2008, 60(S1): A7–A10.
A. Weaver, H. Reiser, T. Barstis, M. Benvenuti, et al. “Paper Analytical Devices for Fast Field Screening of Beta Lactam Antibiotics and Antituberculosis Pharmaceuticals”. Anal. Chem. 2013, 85(13): 6453–6460.
S. Schäfermann, E. Wemakor, C. Hauk, L. Heide. “Quality of Medicines in Southern Togo: Investigation of Antibiotics and of Medicines for Non-Communicable Diseases from Pharmacies and Informal Vendors”. PLoS One. 2018, 13(11): E0207911.
H. Yang, B. Hu, X. Pan, S. Yan, et al. “Deep Belief Network-Based Drug Identification Using Near Infrared Spectroscopy”. J. Innov. Opt. Heal. Sci. 2017, 10(2): 1630011.
H. Yang, B. Hu, X. Pan, S. Yan, et al. “Deep Belief Network-Based Drug Identification Using Near Infrared Spectroscopy”. J. Innov. Opt. Heal. Sci. 2017, 10(2): 1630011.
A. Solangi, S. Memon, M. Khuhawar, M. Bhanger. “Quantitative Analysis of Eight Cephalosporin Antibiotics in Pharmaceutical Products and Urine by Capillary Zone Electrophoresis”. Acta Chromatogr. 2007, 19: 81–96.
N. Tshilombo, P. Hamuli, J. Mbinze, V. Habyalimana, et al. “Investigation of the Quality of Antibiotics-Based Amoxicillin for Monitoring of Some Different Medicine Markets of Democratic Republic of Congo”. Am. J. Anal. Chem. 2018, 9(8): 366–385.
F. Khuluza, S. Kigera, L. Heide. “Low Prevalence of Substandard and Falsified Antimalarial and Antibiotic Medicines in Public and Faith-Based Health Facilities of Southern Malawi”. Am. J. Trop. Med. Hyg. 2017, 96(5): 1124–1135.
I. Fadeyi, M. Lalani, N. Mailk, A. Van Wyk, H. Kaur. “Quality of the Antibiotics—Amoxicillin and Co-Trimoxazole from Ghana, Nigeria, and the United Kingdom”. Am. Soc. Trop. Med. Hyg. 2015, 92(6): 87–94.
A. Weaver, H. Reiser, T. Barstis, M. Benvenuti, et al. “Paper Analytical Devices for Fast Field Screening of Beta Lactam Antibiotics and Antituberculosis Pharmaceuticals”. Anal. Chem. 2013, 85(13): 6453–6460.
O. Rodionova, L. Houmøller, A. Pomerantsev, P. Geladi, et al. “NIR Spectrometry for Counterfeit Drug Detection: A Feasibility Study”. Anal. Chim. Acta. 2005, 549(1–2): 151–158.
S. Bekoe, S. Bak, E. Björklund, K. Krogh, et al. “Determination of Thirteen Antibiotics in Drug Products: A New LC-MS/MS Tool for Screening Drug Product Quality”. Anal. Methods. 2014, 6(15): 5847–5855.
S. Assi, R. Watt, A. Moffat. “Identification of Counterfeit Medicines from the Internet and the World Market Using Near-Infrared Spectroscopy”. Anal. Methods. 2011, 3(10): 2231–2236.
T. Sakamoto, Y. Fujimaki, Y. Hiyama. “NIR Spectroscopic Investigation of Two Fluoroquinolones, Levofloxacin and Ofloxacin, and Their Tablets for Qualitative Identification of Commercial Products on the Market”. Die Pharmazie. 2008, 63(9): 628–632.
A. Pomerantsev, O. Rodionova. “Concept and Role of Extreme Objects in PCA/SIMCA”. J Chemom. 2014, 28(5): 429–438.
T. Kelesidis, L. Kelesidis, P. Rafailidis, M. Falagas. “Counterfeit or Substandard Antimicrobial Drugs: A Review of the Scientific Evidence”. J. Antimicrob. Chemother. 2007, 60: 214–236.
B. Singh, D. Parwate, S. Shukla. “Rapid Color Test Identification System for Screening of Counterfeit Fluoroquinolone”. J. Chem. 2009, 6(2): 377–384.
J. Mbinze, P. Lebrun, B. Debrus, A. Dispas, et al. “Application of an Innovative Design Space Optimization Strategy to the Development of Liquid Chromatographic Methods to Combat Potentially Counterfeit Nonsteroidal Anti-Inflammatory Drugs”. J. Chromatogr. A. 2012, 1263: 113–124.
H. Yang, B. Hu, X. Pan, S. Yan, et al. “Deep Belief Network-Based Drug Identification Using Near Infrared Spectroscopy”. J. Innov. Opt. Heal. Sci. 2017, 10(2): 1630011.
A. Moffat, S. Assi, R. Watt. “Identifying Counterfeit Medicines Using Near Infrared Spectroscopy”. J. Near Infrared Spectrosc. 2010, 18(1): 1–5.
O. Rodionova, K. Balyklova, A. Titova, A. Pomerantsev. “Quantitative Risk Assessment in Classification of Drugs with Identical API Content”. J. Pharm. Biomed. Anal. 2014, 98: 186–192.
S. Assi, R. Watt, A. Moffat. “Assay of Ciprofloxacin in Intact and Powdered Tablets by Near-Infrared Spectroscopy”. J. Pharm. Pharmacol. 2008, 60(S1): A7–A10.
L. Basco, P. Ringwald, A. Manéné, J. Chandenier. “False Chloroquine Resistance in Africa”. Lancet. 1997, 350(9072): 224.
M. Issack. Substandard Drugs”. Lancet. 2001, 358(9291): 1463.
A. Po. “Too Much, Too Little, or None at All: Dealing with Substandard and Fake Drugs”. Lancet. 2001, 357(9272): 1904.
H. Frankish. “WHO Steps Up Campaign on Counterfeit Drugs”. Lancet. 2003, 362(9397): 1730.
D. Menkes. Hazardous Drugs in Developing Countries: The Market May Be Healthier than the People.” Br. Med. J. 1997, 315(7122): 1557–1558.
A. Delepierre, A. Gayot, A. Carpentier. “Update On Counterfeit Antibiotics Worldwide; Public Health Risks”. Med. Maladies Infect. 2012, 42(6): 247–255.
S. Schäfermann, E. Wemakor, C. Hauk, L. Heide. “Quality of Medicines in Southern Togo: Investigation of Antibiotics and of Medicines for Non-Communicable Diseases from Pharmacies and Informal Vendors”. PLoS One. 2018, 13(11): E0207911.
S. Kovacs, S. Hawes, S. Maley, E. Mosites, et al. “Technologies for Detecting Falsified and Substandard Drugs in Low and Middle-Income Countries”. PLoS One. 2014, 9(3): E90601.
R. Brereton. “Consequences of Sample Size, Variable Selection, and Model Validation and Optimization, for Predicting Classification Ability from Analytical Data”. TrAC, Trends Anal. Chem. 2006, 25(11): 1103–1111.
O. Shakoor, R. Taylor, R. Behrens. “Assessment of the Incidence of Substandard Drugs in Developing Countries”. Trop. Med. Int. Health. 1997, 2(9): 839–845.
J. Videau. “Generic Drugs: the Hidden Issues of Quality and Cost”. WHO Drug Information. 2000, 14(2): 77–81.
World Health Organization (WHO). Quality Assurance of Pharmaceuticals. 1999. https://www.who.int/medicines/areas/quality_safety/quality_assurance/qualityassurancepharmvol2.pdf [accessed Jul 21 2020].
World Health Organization (WHO). “Definitions of Substandard and Falsified Medical Products”. 2017. https: //www.who.int/medicines/regulation/ssffc/definitions/en/ [accessed Jul 21 2020].
World Health Organization (WHO). “Counterfeit Drugs: Guidelines for the Development of Measures to Combat Counterfeit Drugs”. 1999. https://apps.who.int/iris/handle/10665/65892 [accessed Jul 21 2020].
S. Pincock. “WHO Tries to Tackle Problem of Counterfeit Medicines in Asia”. Br. Med. J. 2003. 327(7424): 1126.
E. Wondemagegnehu. “WHO Report. Counterfeit and Substandard Drugs in Myanmar and Vietnam”. WHO/EDM/QSM. 1999. https://apps.who.int/iris/handle/10665/66032 [accessed Aug 19 2020].
B. Stenson, B. Lindgren, L. Syhakhang, G. Tomson. “The Quality of Drugs in Private Pharmacies in the Lao People's Democratic Republic”. Int. J. Risk. Saf. Med. 1998. 11(4): 243–249.
Pharmaceutical Security Institute. “Counterfeit Situation”. 2014. http: //www.psi-inc.org/counterfeitsituation.cfm [accessed Jun 13 2020].
C. Hu, W. Zou, W. Hu, X. Ma, et al. “Establishment of a Fast Chemical Identification System for Screening of Counterfeit Drugs of Macrolide Antibiotics”. J. Pharm. Biomed. Anal. 2006. 40(1): 68–74.
United States Pharmacopeia. “<1119> Near-Infrared Spectroscopy”. Rockville, MD: United States Pharmacopoeial Convention. 2019. Pp. 7724–7730.
British Pharmacopoeia Commission. “Near-Infrared Spectrophotometry in the British Pharmacopoeia”. Norwich, UK: British Pharmacopoeia Commission, Stationery Office, 2010. Pp. A150–A154.
R. Jee. “Near-Infrared Spectroscopy”. In: A. Moffat, M. Osselton, B. Widdop, editors. Clarke's Analysis of Drugs and Poisons. London: Pharmaceutical Press, 2004. Pp. 346–357.
K. Varmuza, P. Filzmoser. Introduction to Multivariate Statistical Analysis in Chemometrics., Boca Raton, FL: CRC Press, 2016.
H. Pan, W. Ba-Thein. “Diagnostic Accuracy of Global Pharma Health Fund Minilab in Assessing Pharmacopoeial Quality of Antimicrobials”. Am. J. Trop. Med. Hyg. 2018. 98(1): 344–348.
M. Gaudiano, A. Di Maggio, E. Antoniella, L. Valvo, et al. “An LC Method for the Simultaneous Screening of Some Common Counterfeit and Sub-Standard Antibiotics: Validation and Uncertainty Estimation”. J. Pharm. Biomed. Anal. 2008. 48(2): 303–309.
M.J. Vredenbregt, D. Mooibroek, R. Hoogerbrugge. “Your Viagras––Genuine, Imitation, or Counterfeit?” In: D.A. Burns, E.W. Ciurczak, editors. Handbook of Near-Infrared Spectroscopy. Boca Raton, FL: CRC Press, Taylor and Francis Group, 2008. Chap. 32, Pp. 631–645.
Name | Description |
---|---|
Supplement 1 | sj-pdf-1-asp-10.1177_0003702820958081 - Supplemental material for Authentication of Antibiotics Using Portable Near-Infrared Spectroscopy and Multivariate Data Analysis |
Optica participates in Crossref's Cited-By Linking service. Citing articles from Optica Publishing Group journals and other participating publishers are listed here.